Tempest Therapeutics Inc
(STU:3OS)
€
1.204
-0.031 (-2.51%)
Market Cap: 30.45 Mil
Enterprise Value: 20.58 Mil
PE Ratio: 0
PB Ratio: 1.99
GF Score: 38/100 Tempest Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022 / 04:30PM GMT
Release Date Price:
€1.52
(-3.80%)
James Yoo
Piper Sandler & Co. - Analyst
My name is James Yoo. I'm a healthcare strategist at Piper Sandler. Before I begin, I've been asked to draw your attention to certain disclosures regarding the relationship between Piper Sandler and Tempest posted in the back of the room and at the registration desk. As you know, Tempest is developing first-in-class, targeted, and immune-mediated cancer therapies, including TPST-1120, targeting PPAR-alpha; TPST-1495, targeting the prostaglandin pathway; and a preclinical TREX program.
Joining us from Tempest are CEO Stephen Brady; Tom Dubensky, Ph.D.; and Chief Medical Officer, Sam Whiting, Ph.D. Thank you all for joining us.
Stephen Brady
Tempest Therapeutics, Inc. - CEO & Director
Thank you, James.
Tom Dubensky
Tempest Therapeutics, Inc. - President & Director
Thank you.
Questions & Answers
James Yoo
Piper Sandler & Co. - Analyst
Absolutely. Maybe let's just jump in with TPST-1120, which
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot